Loading stock data…
$61.23-1.10 (-1.76%)
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Cytokinetics, Incorporated in the Healthcare sector is trading at $61.23 with a market capitalization of $10.5B. Wall Street consensus targets $109.20 (20 analysts), implying a +78.3% move over the next 12 months. The stock is currently near its 52-week low of $57.83, remaining 12.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $28.62M↑ | $19.36M↑ | $17.75M↑ | $1.94M↓ | $66.77M |
| Gross Profit | $23.03M↑ | $16.80M↑ | -$86.64M↑ | -$97.30M↓ | $64.35M |
| Operating Income | -$179.17M↑ | -$183.62M↓ | -$178.37M↓ | -$166.75M↓ | -$111.51M |
| Net Income | -$198.76M↑ | -$206.03M↓ | -$183.03M↑ | -$306.18M↓ | -$134.37M |
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets...